Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Asthma; Eosinophilic Clear all
Recruiting Phase 2 Interventional

Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

NCT02947945
View directory record Official record
Conditions
Asthma
Interventions
Reslizumab
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Not applicable Interventional Results available

Eosinophilic Airway Inflammation and Mepolizumab

NCT00802438
View directory record Official record
Conditions
Asthma
Interventions
mepolizumab
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jul 23, 2026, 10:09 AM EDT
Active, not recruiting Phase 4 Interventional

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

NCT03953300
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04719832
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
30
States / cities
Encinitas, California • Long Beach, California • Pasadena, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

NCT01270464
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Anaheim, California • Fountain Valley, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Jul 23, 2026, 10:09 AM EDT
Active, not recruiting Phase 3 Interventional

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

NCT05692180
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 18 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
11
States / cities
Torrance, California • Ocala, Florida • Owensboro, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 10:09 AM EDT
Terminated Phase 3 Interventional

Phase III Long-Term Extension Study With Dexpramipexole

NCT06388889
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Dexpramipexole Dihydrochloride
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Bakersfield, California • Northridge, California • Coral Gables, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

NCT02281318
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, SOC
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Jul 23, 2026, 10:09 AM EDT
Terminated Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

NCT05813288
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma

NCT02099656
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo, Inhaled corticposteroids (ICS), Second Asthma Controller Medication
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

NCT04305405
View directory record Official record
Conditions
Severe Uncontrolled Asthma
Interventions
Benralizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Orlando, Florida • Lincoln, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Results available

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

NCT05552508
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Walnut Creek, California • Loxahatchee Groves, Florida • Plantation, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

NCT03557307
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
23
States / cities
Flagstaff, Arizona • Los Angeles, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Jul 23, 2026, 10:09 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

NCT02937168
View directory record Official record
Conditions
Asthma
Interventions
Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Results available

Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

NCT02654145
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab 100mg SC, Albuterol/salbutamol MDIs, Omalizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • Riverside, California • Roseville, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Jul 23, 2026, 10:09 AM EDT
Active, not recruiting Phase 4 Interventional

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

NCT06041386
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Spirometry
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
28
States / cities
La Jolla, California • Newport Beach, California • Aurora, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

NCT02135692
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, SOC
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Newport Beach, California • Riverside, California • Rolling Hills Estates, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jul 23, 2026, 10:09 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test if TEV-53275 is Effective in Relieving Asthma

NCT04847674
View directory record Official record
Conditions
Asthma
Interventions
TEV-53275 Dose A, TEV-53275 Dose B, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
77
States / cities
Hoover, Alabama • Peoria, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

NCT01287039
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
26
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 23, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

NCT02869438
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Scottsboro, Alabama • Gilbert, Arizona • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Jul 23, 2026, 10:09 AM EDT
Completed No phase listed Observational Results available

Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

NCT05002621
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Observational
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 23, 2026, 10:09 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

NCT01290887
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
48
States / cities
Scottsdale, Arizona • Anaheim, California • Fountain Valley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Jul 23, 2026, 10:09 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
146
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 23, 2026, 10:09 AM EDT